Glaukos Corp Director Mark Foley Sells 4,560 Shares
Director Mark Foley has sold 4,560 shares of Glaukos Corp (NYSE:GKOS) on February 23, 2024, according to a recent SEC Filing. Glaukos Corp is a company that specializes in the development and commercialization of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
Over the past year, the insider has sold a total of 4,560 shares and has not made any purchases of the company's stock. The recent transaction is part of a trend observed over the last year, where there have been no insider buys and 32 insider sells for Glaukos Corp.
On the date of the insider's recent sale, shares of Glaukos Corp were trading at $92.87, giving the company a market capitalization of $4.532 billion.
The stock's valuation, when compared to the GuruFocus Value (GF Value) of $60.27, indicates a price-to-GF-Value ratio of 1.54. This suggests that Glaukos Corp's stock is significantly overvalued based on its GF Value.
The GF Value is a proprietary intrinsic value estimate from GuruFocus, which is determined by considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
